Ovid Therapeutics Inc

NASDAQ:OVIDUnited States

Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.

Contact Information

Headquarters

441 NINTH AVENUE, 14TH FLOORNEW YORK, NY, United States 10001

Phone

212-776-4381

Fax

302-636-5454

Executives

Chairman of the Board, Chief Executive Officer

Jeremy Levin

President, Chief Operating Officer

Margaret Alexander

Chief Business and Financial Officer

Jeffrey Rona

Chief Scientific Officer

Zhong Zhong

Chief Development Officer

Amanda Banks